HRMY
Harmony Biosciences Holdings, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 14 Harmony Biosciences announced the departure of CFO Sandip Kapadia an…
- Jul 16 ▲ Harmony Biosciences pre-announced record Q2 2026 WAKIX net product r…
- Aug 4 ▲ Harmony Biosciences reported record Q2 2026 WAKIX net revenue of $26…
- Aug 4 ▲ Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3M, u…
- Aug 26 Wolfe Research initiates
- Sep 4 to Sep 8 ▼ 2 days of insider sells: $1.5M by 1 insider, avg $42.80
- Sep 16 to Sep 18 ▼ 3 days of insider sells: $1.7M by 1 insider, avg $43.05
- Oct 1 FDA: Harmony Biosciences Announces Poster Presentation at the 1…
- Nov 4 ▼ Earnings: HRMY Q3 2026 Earnings: EPS $0.81 (-30.0% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $3.1M.
- InstitutionsBULLISH
Q3 2026: 36 added (0 new), 18 trimmed or exited.
- AnalystsBULLISH
13 of 18 rate it Buy or better. Median target $49.50 (+50%).
- Short sellersBUILDING
Short interest +23.1% to 6.66M shares. 5.6 days to cover, ≈11.3% of shares.
- TrendDOWNTREND
14% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 7.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Allspring Global Investments Holdings, LLC | DOUBLED | $44.5M |
| Invesco Ltd. | ADD | $27.5M |
| Boston Partners | DOUBLED | $16.6M |
| PRINCIPAL FINANCIAL GROUP INC | ADD | $14.2M |
| FRANKLIN TEMPLETON INC | ADD | $10.1M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $10.1M |
| Creative Planning | ADD | $4.7M |
| HRT FINANCIAL LP | TRIM | $2.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is inside the target range. Median implies +50%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Oct 19, 2026 | Needham REITERATE | Buy |
| Oct 13, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Oct 12, 2026 | Needham REITERATE | Buy |
| Aug 26, 2026 | Wolfe Research INITIATE | Outperform |
| Aug 5, 2026 | Truist Securities MAINTAIN | Hold |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Budur Kumar CHIEF MEDICAL OFFICER Sep 18, 2026 | EXERCISE | $319.4K |
Budur Kumar CHIEF MEDICAL OFFICER Sep 18, 2026 | EXERCISE | $770.3K |
Budur Kumar CHIEF MEDICAL OFFICER Sep 18, 2026 | SELL | $1.5M |
Budur Kumar CHIEF MEDICAL OFFICER Sep 17, 2026 | EXERCISE | $12.1K |
Budur Kumar CHIEF MEDICAL OFFICER Sep 17, 2026 | EXERCISE | $12.3K |
Budur Kumar CHIEF MEDICAL OFFICER Sep 17, 2026 | SELL | $34.4K |
Budur Kumar CHIEF MEDICAL OFFICER Sep 16, 2026 | EXERCISE | $27.6K |
Budur Kumar CHIEF MEDICAL OFFICER Sep 16, 2026 | EXERCISE | $27.2K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
19 filings · 1 press release · 3 bullish · 4 bearish · 2 mixed · 10 neutral- NEUTRAL SC 13GNov 16, 2026
American Century Investment Management disclosed a 5.4% passive stake in Harmony Biosciences as of September 30, 2026, via a new Schedule 13G. This is a routine passive ownership filing by a large asset manager, with no activist intent indicated.
🔒 Fresh report (last 24h), subscribers only
- BEARISH 8-KNov 4, 2026
Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9M (+12% YoY), missing consensus of…
The EPS miss is severe, but revenue growth and reiterated guidance provide a floor. Watch for the ANDA litigation preliminary injunction ruling by Feb 14, 2027, and Phase 1b BP-205 data in Q1 2027…
- BEARISH PRESS-RELEASENov 4, 2026
Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9M (+12% YoY), slightly below the…
The EPS miss is significant but partly driven by one-time milestone charges. Watch for the AET ANDA litigation ruling expected around February 2027, which could impact WAKIX exclusivity. The BP-205…
- NEUTRAL INST-CLUSTERNov 2, 2026
Four institutional investors increased their HRMY positions in Q3 2026, led by Principal Financial…
The cluster shows mild accumulation by mid-tier asset managers but lacks insider support and is dominated by passive or quasi-passive managers. Monitor next quarter's 13F for whether these additions…
All HRMY filing & press-release reports (20)
- SC 13G reportNov 16, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- INST-CLUSTER reportNov 2, 2026
- 8-K/A reportOct 30, 2026
- SC 13G/A reportOct 27, 2026
- 8-K reportOct 13, 2026
- PRESS-RELEASE reportOct 1, 2026
- 8-K reportAug 4, 2026
- PRESS-RELEASE reportAug 4, 2026
- 8-K reportJul 16, 2026
- 144 reportJun 30, 2026
- 144 reportJun 24, 2026
- 144 reportJun 9, 2026
- 144 reportJun 5, 2026
- 3 reportMay 18, 2026
- 8-K reportMay 7, 2026
- 8-K reportApr 14, 2026
- DEFA14A reportApr 3, 2026
- 8-K reportApr 2, 2026